Nader Pourhassan, CytoDyn CEO (Jeff Kravitz/FilmMagic for CytoDyn’s Pro, via Getty Images)
May 17, 2021 04:31 PM EDTUpdated May 21, 03:13 PM
Bioregnum
FDA+

FDA to Cy­to­Dyn: Those 2 Covid tri­als you keep tout­ing both failed on all end­points and your sub­group analy­sis does­n't help. Are we clear now?

As a mat­ter of of­fi­cial pol­i­cy, the FDA doesn’t com­ment about un­ap­proved drugs and the da­ta gath­ered to back them.

As an un­of­fi­cial pol­i­cy, though …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Trump asks 'very tough hom­bre' Dr. Oz to lead MFN talks

End­points 100 biotech sur­vey: Wel­come to the sum­mer of biotech’s dis­con­tent

US warns drug­mak­ers against mis­rep­re­sent­ing cost of im­port­ed prod­ucts

About 5% of CBER and CDER left af­ter FDA staff cuts, analy­sis finds

Meet the ‘first sale’ rule: A cus­toms loop­hole phar­ma com­pa­nies could use to ease tar­iff im­pact

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times